

PRESS RELEASE

AbbVie Expands Biologics Manufacturing Capacity with a \$223 Million Investment in Singapore Manufacturing Site

- US\$223 million expansion will add biologics capacity to AbbVie manufacturing network
- Singapore manufacturing site to grow to more than 500 employees following expansion
- Construction will commence immediately with facilities becoming operational in 2026



AbbVie and Singapore Economic Development Board officials participate in a groundbreaking ceremony on Jan. 25 for AbbVie's \$223 million expansion of its Singapore manufacturing site. Once completed, the new expansion will add new biologics manufacturing capacity to AbbVie's global network and more than 100 new jobs in Singapore.

SINGAPORE Jan. 26, 2024 – AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US\$223 million (S\$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.

Located in Singapore's Tuas Biomedical Park, AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide. This new investment will add 24,000 liters of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within AbbVie's pipeline.

"This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore," said Azita Saleki-Gerhardt, Ph.D., AbbVie Executive Vice President, Chief Operations Officer. "The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline and help AbbVie continue delivering on our patient commitments now and in the future."



With today's announcement, AbbVie has invested more than US\$740 million (S\$1 billion) in acquiring, modernizing and expanding its Singapore facility over the past 10 years. When fully operational, the expanded Singapore manufacturing facility – AbbVie's only manufacturing site in Asia – will employ more than 500 people in manufacturing, quality assurance, supply chain, engineering and administration roles.

“We are delighted that AbbVie has chosen to expand its biologics capacity in Singapore for current and future innovative medicines. We are grateful for AbbVie’s continued trust in the strength of Singapore’s biopharmaceutical manufacturing capabilities and talent base. AbbVie’s investment will enhance Singapore’s leading advanced manufacturing ecosystem and create exciting job opportunities here,” said Cindy Koh, Executive Vice President, Singapore Economic Development Board.

Construction on the expansion will begin later this year, with operations expected to commence in 2026. AbbVie’s Singapore manufacturing plant is a part of AbbVie's Operations team, which consists of 14,000 employees working at more than 30 manufacturing, operations and logistics sites across the United States, Asia, Europe, Puerto Rico and South America.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on [LinkedIn](#), [Facebook](#), [Instagram](#), [X \(formerly Twitter\)](#), and [YouTube](#).

###

Media Contacts

John Torrisi, Director
+1 (224) 213-0055
John.Torrisi@abbvie.com

Yoosook Kim, Director
Yoosook.Kim@abbvie.com